Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

François Bertucci

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0157-0959; OpenAlex author ID A5091721810. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 17

  1. Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer. Co-author DOI 10.1172/jci197733↗
  2. The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage. Co-author DOI 10.1126/sciadv.adu2276↗
  3. Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer. Co-author DOI 10.1186/s12964-023-01388-7↗
  4. SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2021-326610↗
  5. A Lesson in Transcriptional Plasticity: Classical Identity Is Silenced, but Not Lost, in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.1053/j.gastro.2022.07.005↗
  6. CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. Co-author DOI 10.1126/scisignal.abg8191↗
  7. Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. Co-author DOI 10.15252/embj.2021110466↗
  8. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s42003-021-02508-0↗
  9. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1039↗
  10. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter. Last author DOI 10.1158/1078-0432.ccr-20-1969↗
  11. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0439↗
  12. XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. Last author DOI 10.3390/jcm8050596↗
  13. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. First author DOI 10.1016/j.bbcan.2018.02.001↗
  14. Prognostic Value of Molecular Subtypes in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000787↗
  15. A 25-gene classifier predicts overall survival in resectable pancreatic cancer. Last author DOI 10.1186/s12916-017-0936-z↗
  16. Prognostic value of PDL1 expression in pancreatic cancer. Last author DOI 10.18632/oncotarget.11685↗
  17. Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma. First author PMID 27107061↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard Tomasini · 7 shared papers, 2021–2026 · strength 1.17
  2. David Jérémie Birnbaum · 10 shared papers, 2016–2022 · strength 0.99
  3. Daniel Birnbaum · 9 shared papers, 2016–2021 · strength 0.82
  4. Zainab Hussain · 4 shared papers, 2023–2026 · strength 0.81
  5. Sophie Vasseur · 5 shared papers, 2021–2026 · strength 0.80
  6. Émilie Mamessier · 7 shared papers, 2016–2024 · strength 0.69
  7. Fabienne Guillaumond · 4 shared papers, 2021–2025 · strength 0.56
  8. Moacyr Jesus Barreto de Melo Rêgo · 2 shared papers, 2024–2026 · strength 0.46
  9. Jérémy Nigri · 3 shared papers, 2022–2023 · strength 0.40
  10. Juan Iovanna · 3 shared papers, 2021–2022 · strength 0.36
  11. Andrew Louis Warshaw · 3 shared papers, 2020–2022 · strength 0.35
  12. Andrew Scott Liss · 3 shared papers, 2020–2022 · strength 0.35
  13. Keith D. Lillemoe · 3 shared papers, 2020–2022 · strength 0.35
  14. Georgios Efthymiou · 2 shared papers, 2023–2025 · strength 0.35
  15. Nelson Dusetti · 2 shared papers, 2022–2023 · strength 0.26
  16. Julie Leca · 2 shared papers, 2022 · strength 0.25
  17. Jean‐Luc Raoul · 4 shared papers, 2016–2017 · strength 0.24
  18. Flora Poizat · 3 shared papers, 2016–2017 · strength 0.19
  19. Marine Gilabert · 3 shared papers, 2016–2017 · strength 0.19
  20. David Tsai Ting · 2 shared papers, 2020–2021 · strength 0.19
  21. Carlos F. Fernandez-del Castillo · 2 shared papers, 2020–2021 · strength 0.19
  22. Thomas P. Hank · 2 shared papers, 2020–2021 · strength 0.19
  23. Sebastian K.S. Begg · 2 shared papers, 2020–2021 · strength 0.19
  24. Mari A. Mino-Kenudson · 2 shared papers, 2020–2021 · strength 0.19
  25. Jean‐Robert Delpéro · 3 shared papers, 2016–2017 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.